{
    "nctId": "NCT01288261",
    "briefTitle": "Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer",
    "officialTitle": "A Phase I Trial of Weekly Paclitaxel in Combination With Bavituximab in Patients With Her-2 Negative Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Determination of grade 3 or higher toxicities associated with the combination therapy as classified using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent has been obtained\n* Life expectancy of at least 3 months\n* Histologically or cytologically confirmed, Her-2 negative breast cancer with evidence of metastatic disease\n* Measurable or evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST)\n* Eastern Cooperative Oncology Group (ECOG) Performance Status =\\< 2\n* Adequate hematologic function (absolute neutrophil count \\[ANC\\] \\>= 1,500 cells/uL; hemoglobin \\>= 9 g/dL; platelets \\>= 100,000/uL and =\\< 500,000/uL)\n* Adequate renal function (serum creatinine =\\< 1.5 mg/dL or calculated creatinine clearance \\>= 60 ml/min)\n* Adequate hepatic function (total or direct bilirubin =\\< Upper Limit of Normal (ULN), Alk Phos =\\< 4 x ULN)\n* Prothrombin time international normalized ratio within institutional normal limits\n* Activated partial thromboplastin time =\\< 1.5 x ULN\n* New York Heart Association classification I or II\n* Female patients must have a negative urine pregnancy test at prestudy (not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal)\n\nExclusion Criteria:\n\n* Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand Disease, Hemophilia)\n* Any current evidence of clinically significant active bleeding\n* Any history of significant thromboembolic events (i.e., deep vein thrombosis or pulmonary thromboembolism) within the last five years or requirement for ongoing therapy with oral or parenteral anticoagulants; central venous catheter-related thrombosis \\> 12 months ago and low dose anticoagulants to maintain patency of lines are allowed; patients taking anticoagulants (e.g., prophylactic heparin or enoxaparin) are required to observe the washout period of 1 week prior to study drug infusion on Study Day 1\n* Concurrent hormone therapy (i.e., estrogen contraceptives, hormone replacement, anti-estrogen); patients taking concurrent hormone therapy are required to observe the washout period of 2 weeks prior to study drug infusion on Study Day 1\n* Grade 2 or higher peripheral neuropathy (e.g., numbness, tingling, and/or pain in distal extremities)\n* More than one prior chemotherapy regimen for metastatic disease (prior adjuvant chemotherapy or any number of prior hormonal therapies are allowed)\n* Chemotherapy, immunotherapy or radiotherapy within 2 weeks of Study Day 1 or not having recovered from significant treatment-related side effects due to agents administered previously; patients who have receive nitrosoureas and mitomycin C therapy are required to observe the washout period of 6 weeks prior to study drug infusion on Study Day 1\n* Allergy to polysorbate 80 or drugs containing polyoxyethylated castor oil (e.g. cyclosporine)\n* Symptomatic or clinically active Central Nervous System (CNS) disease\n* Major surgery within 4 weeks of Study Day 1\n* Female patients pregnant or nursing\n* All patients of reproductive potential must agree to use appropriate non-hormonal form of contraception\n* Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease)\n* Any history of angina pectoris, coronary artery disease or cerebrovascular accident, or transient ischemic attack\n* A history of any condition requiring anti-platelet therapy (e.g., phosphodiesterase inhibitors, adenosine diphosphate receptor antagonists) with the exception of general cardiovascular prophylaxis with aspirin\n* Cardiac arrhythmia requiring medical therapy\n* Serious non-healing wound (including wound healing by secondary intention, ulcer, or bone fracture)\n* Requirement for chronic daily steroid use\n* Known chronic infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}